Related Experiment Video
Updated: Sep 29, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Improving outcomes for older hypertensive patients: is more intensive treatment better?
Yue Deng1, Yunlan Liu2, Li Yang3
1Hypertension Center, FuWai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, Hebei, China.
Insights
Lowering systolic blood pressure (SBP) to below 130 mmHg in older adults with hypertension offers significant cardiovascular benefits and is safe. This intensive SBP target should be considered for broader guideline recommendations.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Hypertension Management
Background:
- Late-life hypertension is a growing concern with aging populations.
- Current guidelines may not reflect optimal systolic blood pressure (SBP) targets for older adults.
- Evidence suggests additional cardiovascular benefits from more intensive SBP reduction.
Purpose of the Study:
- To review the evolving understanding of late-life hypertension.
- To discuss the optimal SBP target for older hypertensive patients.
- To analyze recent evidence on intensive SBP treatment in this demographic.
Main Methods:
- Review of antihypertensive drug-placebo studies.
- Analysis of blood pressure target studies in older adults.
- Inclusion of high-quality meta-analyses on intensive SBP treatment.
Main Results:
- A systolic blood pressure (SBP) target of <130 mmHg is safe and beneficial for most older hypertensive patients.
- Benefits are observed, though potentially to a lesser degree, in older patients with comorbidities like CKD or diabetes.
- Intensive SBP targets require judicious application in specific extreme conditions.
Conclusions:
- Robust evidence supports a <130 mmHg SBP target for older adults with hypertension.
- Current relaxed SBP targets in guidelines need revision to <130 mmHg.
- This intensive approach offers additional cardiovascular protection in the elderly.
Introduction:
With population aging, late-life hypertension is becoming an increasingly important issue. Mounting evidence has documented additional cardiovascular benefits induced by a more intensive target, lower than what are recommended in most current guidelines for systolic blood pressure (SBP) reduction in older patients with hypertension. However, the optimal target remains less clear.
Areas Covered:
In the present review, we summarized the evolution of the perspective into late-life hypertension and the development of the 'optimal' target for SBP reduction in older patients with hypertension. More importantly, new evidence from latest antihypertensive drug-placebo studies, blood pressure target studies, and high-quality meta-analysis regarding the effect of intensive SBP treatment in older patients were covered and discussed in detail.
Expert Opinion:
In summary, robust evidence supports that a SBP target of <130 mmHg is safe and will induce additional cardiovascular benefits in general older patients with hypertension. This benefit seems to be consistent, but less degreed in older patients with comorbidities such as chronic kidney disease or diabetes mellitus. However, such an intensive SBP target should be judiciously applied in older patients under extreme conditions. Collectively, edging down the relaxed SBP targets to <130 mmHg in most of the current guidelines is in imperative need.
Related Concept Videos
Hypertension V: Nursing Management
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension III: Clinical Manifestations and Diagnostic Studies
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Hypertension I: Introduction

